Sign in
ITCI Stock Price, Chart, Stats & News
Intra-Cellular Therapies, Inc.
Save
14.05B
Market cap
–
Current P/E
–
Forward P/E
ITCI chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 90.46% |
Operating margin | -18.18% |
Pretax margin | -11.53% |
Net margin | -11.54% |
Effective tax rate | -0.13% |
ROA | -3.16% |
ROE | -3.77% |
D/E | 0.01x |
Interest coverage ratio | – |
ITCI valuation
P/E | – |
P/S | 37.52x |
P/B | 11.84x |
P/CF | -343.41x |
P/FCF | -352.30x |
P/OCF | -343.41x |
PEG | -3.18x |
EV multiple | -211.46x |
About
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on creating innovative treatments for conditions affecting the brain and nervous system. The company achieves this by targeting the intricate cellular communication pathways within the central nervous system, primarily operating in the United States. Its commercialized product is CAPLYTA, an approved therapy for schizophrenia in adult patients.
Similar securities
Based on sector and market capitalization
Report issue